1 |
K. M. Lee, K. C. Lee, The Effects of R & D Investment in Korean Pharmaceutical Industry on Firm Performance, Research of Professional Managers, vol.10, No.2, pp.81-101, 2007
|
2 |
DiMasi JA, Hansen RW, H. G. Grabowski.The price of innovation: new estimates of drug development costs Jos, Research Technology Management, Vol.46, No.5, pp.64, 2003
|
3 |
S. J. Lee, Intangible assets Accounting change, DAILYPHARM, 2018, http://www.dailypharm.com/ (accessed Oct.4,2019)
|
4 |
S. Y. Park, S. P. Cho, Comparison of Research and Development Activities of Domestic Companies and Implications, Korea Institute of Science and Technology Evaluation and Planning, 2007.
|
5 |
S. H. Shin, D. H Lee, The relevance of IFRS adoption to accounting for R & D expenses. Journal of Business Administration, Vol.15, No 2, pp.1-23, 2007.
|
6 |
M. T. Kim, The Effects of Capitalization on R & D Expenditure on Profit Management in the Pharmaceutical Industry, Journal of Financial and Accounting Information, Vol.16, No.1, 2016.
|
7 |
K. S. Kim, W. T. Kim, S. S. Park, D. H. Jang and C. Y. Lee, Estimation of Tobin's Q for Korean Listed Firms). Analysis of the Korean economy, vol. 2, No.2, pp.147-75, 1996.
|
8 |
J. H. Ahn, The Effect of Research and Development Costs of External Audit IT Firms on Accounting Corporate Performance-Analysis Using Panel data, Pusan University, Economic Master's. thesis, 2017.
|
9 |
K. H. Yook, Review of R & D and economic effects of advertising expenditure. JOURNAL OF BUSINESS RESEARCH, Vol.18, pp219-51, 2003.
DOI
|
10 |
K. S. Bae, The Impact of the Development Cost of Intangible Assets of Life Company on Corporate Value, Chungbuk National University, 2015.
|
11 |
J. G. Lee, The Effects of Corporate Characteristics on the Relationship between R & D and Corporate Value. Financial Engineering Research. 9, pp.77-101, 2010.
|
12 |
J. H. Kim,. The impact of R & D spending on firm profit and firm value. InternationalAccounting Research, Vol.19, pp.139-55, 2007.
|
13 |
J. S. Choi, Y. M. Kwak J. H. Sohn, KOSDAQ Newly listed companies seeking profit adjustment and managerial private profit. Accounting Studies, Vol.35 No.3, pp.37-80, 2010.
|
14 |
E. S. Lee, Comparison of R & D Capitalization of Pharmaceutical Companies. Accounting Information Research, Vol.33, No.2, pp.141-59, 2015.
|
15 |
S. Y. Park, Managerial Opportunity for Earnings Announcement and Accuracy of Preliminary Earnings. The Korean Academic Association of Business Administration, Vol.31, No.9, pp.1665-86, 2018.
DOI
|
16 |
D. W. Kim, S. M, Jang and H, J Song, Determinants of R & D investment scale of pharmaceutical companies, Health Economy and Policy Research, Vol.6, No.2, 2010.
|